TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00196781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CD-ROM-based prostate cancer treatment education
Description: The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CD-ROM-based prostate ca treatment education+decision tools
Description: The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
Study: NCT01760148

Intervention type: DRUG
Intervention: interferon alpha 2b
Description: Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
Study: NCT02367599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
Study: NCT04272398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic elastomeric fabric orthoses
Description: Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic elastomeric fabric orthoses
Description: Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
Study: NCT01574703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: All dosing to have taken place per study A3051123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline tartrate
Description: All dosing to have taken place per study A3051123
Study: NCT02838888

Intervention type: DEVICE
Intervention: Automatic polyp detection software
Description: A computer program for the detection of colonic polyps will be used during colonoscopy
Study: NCT02061293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement and Taking Action (META)
Description: Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
Study: NCT06247267

Intervention type: DRUG
Intervention: Fortesta
Description: Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.

Intervention type: DRUG
Intervention: Estradiol
Description: Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.

Intervention type: DRUG
Intervention: Fortesta
Description: Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
Study: NCT01493388

Intervention type: DRUG
Intervention: insulin
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician.
Study: NCT00908193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic DA VINCI Robot Assisted coelioscopy
Description: Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional coelioscopy
Description: Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
Study: NCT03317509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic (rTMS)
Description: Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
Study: NCT02061293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement and Taking Action (META)
Description: Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
Study: NCT01243853

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-galactosidase
Description: 3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-galactosidase
Description: 3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
Study: NCT00564876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
Study: NCT02866201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal swab
Study: NCT01958619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg PQP tablets
Description: Piperaquine phosphate tablets (1440mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP tablets
Description: Piperaquine phosphate tablets (960mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 + TPGS
Description: OZ439 (800mg) + TPGS granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 + TPGS
Description: OZ439 (800mg) + TPGS granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 + TPGS
Description: OZ439 (800mg) + TPGS granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 + TPGS
Description: OZ439 (800mg) + TPGS granules for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP granules
Description: Piperaquine phosphate granules for oral solution (960mg)
Study: NCT01574703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: All dosing to have taken place per study A3051123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Patch
Description: All dosing to have taken place per study A3051123
Study: NCT03818334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1000 mg/flask

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
Study: NCT04066894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Explantation
Description: Undergo lead removal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00964067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
Study: NCT04066894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulator
Description: Undergo sacral nerve stimulator implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulator Battery
Description: Undergo sacral nerve stimulator battery implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo sacral nerve stimulator implantation
Study: NCT02302118

Intervention type: PROCEDURE
Intervention: Esophagogastrectomy
Description: Esophagogastrectomy
Study: NCT00743873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: US guided IM injection 3-6mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 6 cc of saline into injured area
Study: NCT02391194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-620
Study: NCT03541408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard Of Care without Preventative Delirium Protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventative Delirium Protocol
Description: Preventative Delirium Protocol
Study: NCT03376243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIPIKAR BAUME AP+ emollient
Description: Structured education on prevention guidelines
Study: NCT00350766

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation
Description: Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation
Description: Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
Study: NCT02942758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose Azacitidine
Description: Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 45 mg p.o. continuously from day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
Study: NCT00964067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
Study: NCT02942758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose AZA
Description: Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
Study: NCT00940628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: mildly hypocaloric diet and physical exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet and Exercise
Description: mildly hypocaloric diet and physical exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat [Xenical]
Description: 120mg po tid
Study: NCT03077919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% ropivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: preservative-free normal saline
Study: NCT03079063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, biosimilar
Description: Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novoseven
Description: Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
Study: NCT04628429

Intervention type: DRUG
Intervention: Erenumab
Description: anti-CGRP-receptor monoclonal anti-body
Study: NCT03783767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Intervention
Description: Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
Study: NCT03694509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast tea with full fat milk
Description: Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
Study: NCT00004918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study: NCT01826929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Study: NCT01420770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT03383276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Description: custom eye drop to be applied to the left eye.
Study: NCT03770806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Nerve Block
Description: Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Block
Description: routine iv and oral pain medication alone-observation only
Study: NCT03864406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Each tablet of Tybost contains 150 mg of cobicistat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Each tablet of Xarelto contains 10 mg of rivaroxaban.
Study: NCT03237325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX942
Description: 1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
Study: NCT00944528

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Single dose or radiation in 15Gy, 18Gy or 21Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Single dose or radiation in 15Gy, 18Gy or 21Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Single dose or radiation in 15Gy, 18Gy or 21Gy
Study: NCT00004918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study: NCT02329951

Intervention type: PROCEDURE
Intervention: Facet intervention
Description: Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns

Intervention type: PROCEDURE
Intervention: Sacroiliac joint injection
Description: Injection of steroid and local anesthetic into SI joint
Study: NCT03694509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water 250ml.
Study: NCT02090088

Intervention type: DRUG
Intervention: Not applicable- observational study
Study: NCT03379337

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dental imaging
Description: The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
Study: NCT03349021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bougiecap
Description: Treatment of esophagel Stenosis by Bougiecap
Study: NCT02969382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: One Placebo capsule daily for 4 weeks
Study: NCT04705792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
Study: NCT01946750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stools

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stools

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saliva
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
Study: NCT02329951

Intervention type: PROCEDURE
Intervention: Epidural steroid injection
Description: Transforaminal or interlaminar injection of steroid epidurally
Study: NCT02208427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine and Isoniazid for 3 months
Description: weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid for 9 months
Description: daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
Study: NCT03876795

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Concentrate
Description: Bone Marrow Concentrate injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: Bone Marrow Concentrate injection
Study: NCT00422058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orlistat
Description: 120 mg capsule. Administered thrice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c. (under the skin) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Injected s.c. (under the skin) once daily